ACA
ESPR

Affinity Capital Advisors’s Esperion Therapeutics ESPR Stock Holding History

Affinity Capital Advisors’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$31.5K Hold
10,000
– – ﹤0.01% 201
2026
Q1 		$27.4K Hold
10,000
– – ﹤0.01% 180
2025
Q4 		$37K Hold
10,000
– – 0.01% 172
2025
Q3 		$29K Hold
10,000
– – ﹤0.01% 152
2025
Q2 		$9.84K Hold
10,000
– – ﹤0.01% 159
2025
Q1 		$10.2K Buy
+10,000
New +$18.4K ﹤0.01% 154

Other funds holding ESPR

GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TC
Trium Capital London, United Kingdom $163M AUM 45.8% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $7.02B AUM 31.58% 1-Year Est. Return
OBAM
ODDO BHF Asset Management Paris, France $2.16B AUM 43.32% 1-Year Est. Return

Affinity Capital Advisors's ESPR Position: Q2 2026 in Review

Affinity Capital Advisors held its Esperion Therapeutics (ESPR) position steady in Q2 2026 at 10,000 shares worth $31.5K. The position accounts for ﹤0.01% of the portfolio, ranked #201.

Affinity Capital Advisors first reported a position in ESPR in Q1 2025 and has held it in 6 quarters since. The position peaked at $37K in Q4 2025. 191 funds tracked by Wall St. Rank hold ESPR as of Q2 2026.

  • Affinity Capital Advisors held 10,000 shares of Esperion Therapeutics worth $31.5K as of Q2 2026.
  • Affinity Capital Advisors left its Esperion Therapeutics share count unchanged in Q2 2026.
  • Esperion Therapeutics made up ﹤0.01% of Affinity Capital Advisors's portfolio in Q2 2026, its #201 holding.
  • Affinity Capital Advisors first reported a position in Esperion Therapeutics in Q1 2025 and has held it in 6 quarters since.
  • Affinity Capital Advisors's Esperion Therapeutics position peaked at $37K in Q4 2025.
  • 191 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q2 2026.

Based on Affinity Capital Advisors's 13F filing for Q2 2026, filed 8 Jul 2026.